| OP-1 |
TREATMENT ACCESSIBILITY, AVAILABILITY, AND HEALTHCARE COSTS FOR MULTIPLE MYELOMA IN SOUTH ASIAN COUNTRIES |
CLINICAL-MM |
| OP-2 |
COMPREHENSIVE CLINICOPATHOLOGICAL ANALYSIS OF RENAL MANIFESTATIONS IN MYELOMA- A PROSPECTIVE COHORT |
CLINICAL -MM |
| OP-3 |
POST AUTOLOGOUS TRANSPLANT OUTCOMES IN HIGH RISK VS. NON HIGH RISK MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE. |
CLINICAL-MM |
| OP-4 |
THE EARLY IMPRESSIONS WITH THE USE OF BISPECIFIC ANTIBODIES IN MULTIPLY RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SAFETY AND EFFICACY ANALYSIS. |
CLINICAL-MM |
| OP-5 |
PREDICTORS OF TRANSPLANT OUTCOMES IN PATIENTS WITH PLASMA CELL DYSCRASIA. |
CLINICAL-MM |
| OP-6 |
REDUCED-DOSE LENALIDOMIDE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A COMPARATIVE PILOT STUDY OF TREATMENT RESPONSES WITH STANDARD-DOSE VRD THERAPY |
CLINICAL-MM |
| OP-7 |
SOLITARY PLASMACYTOMA - A RETROSPRCTIVE STUDY OF SURVIVAL OUTCOMES IN A TERTIARY CARE CENTER |
CLINICAL-MM |
| OP-8 |
BARRIERS TO AUTOLOGOUS STEM CELL TRANSPLANTATION AND THEIR IMPACT ON OUTCOMES IN MULTIPLE MYELOMA: A SINGLE CENTRE STUDY |
CLINICAL-MM |
| OP-9 |
LONG TERM OUTCOMES OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA - A RETROSPECTIVE OBSERVATIONAL STUDY FROM A TERTIARY CARE CENTRE |
CLINICAL-MM |
| OP-10 |
PROGNOSTIC SIGNIFICANCE OF BASELINE SERUM FERRITIN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A RETROSPECTIVE STUDY IN SOUTH INDIAN PATIENTS. |
CLINICAL-MM |
| OP-11 |
THE ROLE OF SEQUENTIAL COMPOSITE MEASURABLE RESIDUAL DISEASE ASSESSMENT USING PET-CT AND BONE MARROW FLOWCYTOMETRY IN MULTIPLE MYELOMA PATIENTS TREATED WITH EXTENDED INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANT: REAL-WORLD INSIGHTS |
CLINICAL-MM |
| OP-12 |
SECOND PRIMARY MALIGNANCIES POST AUTOLOGOUS STEM-CELL TRANSPLANT IN MULTIPLE MYELOMA FROM INDIA ? KNOWING THE UNKNOWN |
CLINICAL-MM |
| OP-13 |
DOUBLET VS TRIPLET THERAPY IN ELDERLY MULTIPLE MYELOMA |
CLINICAL-MM |
| OP-14 |
PROGNOSTIC RELEVANCE OF PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE ASSESSMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA |
CLINICAL-MM |
| OP-15 |
OUTCOMES IN MULTIPLE MYELOMA POST HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FROM CANCER INSTITUTE, CHENNAI |
CLINICAL-MM |
| OP-16 |
MAPPING THE REGIONAL DISPARITIES AND RESEARCH TRENDS IN MULTIPLE MYELOMA CLINICAL TRIALS: A FOCUS ON SOUTH AND SOUTHEAST ASIA |
CLINICAL-MM |
| OP-17 |
PRIMARY REFRACTORY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INCIDENCE, CHARECTERISTICS AND OUTCOME FROM A TERTIARY CANCER CENTRE IN INDIA. |
CLINICAL-MM |
| OP-18 |
OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH +1Q CYTOGENETIC ABNORMALITIES: A COMPREHENSIVE ANALYSIS |
CLINICAL-MM |
| OP-19 |
REAL-WORLD ANALYSIS OF PROLONGED LENALIDOMIDE INDUCTION THERAPY AND ITS IMPACT ON STEM CELL MOBILISATION FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA |
CLINICAL-MM |
| OP-20 |
OUTCOMES OF AUTOLOGOUS STEM-CELL TRANSPLANT AS PER MELPHALAN DOSE IN PATIENTS WITH MULTIPLE MYELOMA ? A 15-YEAR RETROSPECTIVE INSTITUTIONAL ANALYSIS |
CLINICAL-MM |
| OP-21 |
A RETROSPECTIVE AUDIT OF PRIMARY PLASMA CELL LEUKEMIA FROM A SINGLE TERTIARY CARE CENTER IN EASTERN INDIA |
PCD- PLASMA CELL LEUKAEMIA |
| OP-22 |
PLASMA CELL LEUKEMIA: A DECADE OF REAL-WORLD INSIGHTS AND OUTCOMES? |
PCD-PLASMA CELL LEUKAEMIA |
| OP-23 |
EVOLVING LANDSCAPE OF AL AMYLOIDOSIS: A SINGLE CENTRE EXPERIENCE OF TWO DECADES |
PCD- AMYLOIDOSIS |
| OP-24 |
CLINICAL CHARACTERISTICS AND LONG TERM OUTCOMES OF POEMS SYNDROME FROM A TERTIARY CARE CANCER CENTER IN INDIA |
PCD-WALDENSTROMSMACROGLOBULINEMIA, POEMS |
| OP-25 |
MASS SPECTROMETRIC EXPLORATION OF BICLONAL GAMMOPATHY: DIAGNOSTIC EVIDENCE OR THERAPEUTIC INTERFERENCE |
LABORATORY-PARAPROTEINEMIA |
| OP-26 |
CHARACTERIZING THE DNA METHYLATION LANDSCAPE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA |
LABORATORY-IMMUNOLOGICAL |
| OP-27 |
ESTIMATING THE REFERENCE INTERVAL FOR SOLUBLE B-CELL MATURATION ANTIGEN (SBCMA)IN HEALTHY SOUTH INDIAN ADULTS: INSIGHTS FROM A SINGLE CENTER STUDY |
LABORATORY |
| OP-28 |
RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-BETA LIGAND (RANKL) EXPRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA |
PATHOLOGICAL |
| OP-29 |
STUDY OF CLINICO-IMMUNOHEMATOLOGICAL PROFILE OF MULTIPLE MYELOMA (MM) AND MEASURABLE RESIDUAL DISEASE (MRD) MONITORING BY FLOW CYTOMETRIC ANALYSIS OF BONE MARROW AND CIRCULATING CLONAL PLASMA |
PATHOLOGICAL |
| OP-30 |
IMMUNOPHENOTYPING PROFILE AND MEASURABLE RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA - AN EXPERIENCE FROM A TERTIARY CARE CENTRE IN SOUTHERN INDIA |
PATHOLOGICAL |
| OP-31 |
CIRCULATING CLONAL PLASMA CELLS AND ITS ASSOCIATION WITH PROGNOSTIC MARKERS IN MULTIPLE MYELOMA |
PATHOLOGICAL |
| OP-32 |
EXPLORING THE ASSOCIATIONS OF TP53 GENE ABERRATIONS AMONGST ROUTINE DIAGNOSTIC INVESTIGATIONS IN MULTIPLE MYELOMA PATIENTS. |
PATHOLOGICAL |
| OP-33 |
QUANTITY OF BONE MARROW MESENCHYMAL STROMAL CELLS (BMMSC) IS ASSOCIATED WITH LOAD OF CIRCULATING TUMOR PLASMA CELLS IN NEWLY DIAGNOSED MULTIPLE MYELOMA. |
PATHOLOGICAL |
